China's original exclusive drug hydrobromobromate 菪 is expected to be available this year

China's original drugs listed this year mainly in the field of vertigo drugs recently industry news shows that by Chengdu First Pharmaceutical Co., Ltd. (referred to as: Cheng one pharmaceutical) research and development of the exclusive drug hydrobrominatebase tablets will be approved for listing in 2021, the main vertigo, anti-spasm pain target market areas.
public information shows that hydrobrominatebase was developed by the Institute of Pharmaceutical Research of the Chinese Academy of Medical Sciences, for the extraction offrom the aubergine plant Tanggut mountain , after artemisinin, China's original drugs.
has obvious external weekly anticholinel effect (slack smooth muscle, relieve microvascular spasms), the effect is similar to Athosin, but has the advantages of higher exo-weekly selectivity and lower side effects.
the 2018 version of the national base medicine, the 2020 version of the health insurance Class A (national shortage of drugs), emergency rescue and critically ill medication, with a unique "vertigo" adaptive disorder.
anti-vertigo drug market potential huge counter-trend rose 25.66% public data show that vertigo is due to the body's spatial positioning disorders caused by a motor or positional illusion, according to the occurrence of the disease is divided into peripheral vertigo, central vertigo.
Anti-vertigo drugs can play a role in eliminating dizziness, promote the brain to establish a new sense of balance, reduce nausea, vomiting, anxiety and other effects, clinically can be used for peripheral dizziness: otolaryngology, Meniere disease, sudden deafness;
China's public medical institutions terminal vertigo drug sales (units: 100 million yuan) Source: Minnet Mi intranet data show that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal vertigo drug (chemical drugs and Chinese medicine) market continued to expand, the growth rate remained in double digits, in 2019 achieved sales revenue of 2.681 billion yuan, an increase of 17.58 percent year-on-year.
2020H1 affected by the new crown outbreak, sales of several drug categories fell, but anti-vertigo drugs are still rising against the trend, growth rate of more than 25%, which shows that the field has a steady rise in market potential.
Hydrobrominate yam alkali injection sales growth rate of 280% in recent years hydrobrominate statins alkali outbursts, the market share increased year by year, breaking the anti-vertigo drug statins "one product unique" market pattern, of which hydrobromobrominatebase injection 4 years compound growth rate of 280%.
, according to the enterprise, hydrobrominatebase injection in 2020 the national market will achieve sales of more than 300 million yuan, the future growth space is still huge.
Figure 3: Sales of end-level hydrobrominate -alkali injections in China's public medical institutions (units: 100 million yuan) Source: Minnet China's public medical institutions terminal competition pattern "2017 vertigo diagnosis and treatment multidisciplinary expert consensus" "2020 dizziness/dizziness" Guidelines such as the Guidelines for The Diagnosis and Treatment of Meniere Disease 2017 (Practical Edition 2019) show that commonly used drugs for the treatment of vertigo include antihistamines, anticholinel energy agents and benzodiazepines 䓬.
tablets listed powerful impact vertigo drug oral preparations market by Chengdu First Pharmaceutical exclusive production of hydrobromohetic yamsalkali tablets will be listed for sale in 2021, approved adaptive "to alleviate smooth muscle spasms, vertigo, microcirculation disorders and organophosphate pesticide poisoning."
In 2019, China's public medical institutions terminal vertigo oral drug market size exceeded 1.1 billion yuan, hydrobrominate yambase tablets a variety of guidelines, both base drugs, medical insurance Class A characteristics, the existing hydrobrominate sage base injection market will form a beneficial supplement.
Hydrobromite alkali tablets are also suitable for urinary stones, gallbladderitis, gastrointestinal inflammation, irritable bowel syndrome, endoscopy and other diseases, the market opportunities and potential is huge.